Failure is not an option: How to avoid and recover from an IND clinical hold
RF QuarterlyLinda McBride, RPh, RAC • Ben McLaughlin, MSE • Tyler Vandivort, PhD, RAC-Drugs, DABT
Chemistry, Manufacturing and Controls (CMC)Clinical TrialsPharmaceuticalsRegulatory strategyUnited States